Related Experiment Video
Updated: May 11, 2026
09:39
Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
Published on: February 7, 2021
Injectable nano-network for glucose-mediated insulin delivery.
Zhen Gu1, Alex A Aimetti, Qun Wang
1Department of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
ACS Nano
|May 4, 2013
Summary
This study presents a novel injectable nano-network for diabetes management. The system self-regulates insulin release based on glucose levels, improving blood glucose control in diabetic mice for up to 10 days.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Endocrinology
Background:
- Diabetes mellitus is a global health issue affecting millions worldwide.
- Current diabetes management often faces challenges with patient compliance and maintaining optimal glucose levels.
- Artificial closed-loop systems offer a promising approach to mimic natural pancreas function for improved insulin delivery.
Purpose of the Study:
- To develop an injectable, acid-degradable polymeric network for self-regulated insulin delivery.
- To create a glucose-mediated system that releases insulin in response to hyperglycemia.
- To evaluate the efficacy of this novel system in controlling blood glucose levels.
Main Methods:
- Formulation of dextran nanoparticles loaded with insulin and glucose-specific enzymes.
- Creation of a nanocomposite-based porous architecture via electrostatic interactions.
- In vitro assessment of glucose-responsive insulin release profiles.
- In vivo studies in type 1 diabetic mice to evaluate glucose control after nano-network administration.
Main Results:
- The developed nano-network demonstrated glucose-mediated and pulsatile insulin release in vitro.
- In vivo studies showed improved glucose control in type 1 diabetic mice.
- A single injection stabilized blood glucose levels in the normoglycemic range (<200 mg/dL) for up to 10 days.
Conclusions:
- The injectable, acid-degradable nano-network represents a viable strategy for self-regulated insulin delivery.
- This glucose-responsive system has the potential to enhance diabetes management and patient outcomes.
- The formulation offers a promising approach for long-term stabilization of blood glucose levels.
More Related Videos
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...